Genmab A/S (CPH: GMAB)
Denmark
· Delayed Price · Currency is DKK 1,462.00
+8.00 (0.55%)
Dec 20, 2024, 4:59 PM CET
Genmab Revenue
Genmab had revenue of 5.54B DKK in the quarter ending September 30, 2024, with 17.57% growth. This brings the company's revenue in the last twelve months to 19.84B, up 17.75% year-over-year. In the year 2023, Genmab had annual revenue of 16.47B with 13.57% growth.
Revenue (ttm)
19.84B
Revenue Growth
+17.75%
P/S Ratio
4.76
Revenue / Employee
7.53M
Employees
2,204
Market Cap
92.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | 5.37B | 2.34B | 77.39% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk A/S | 270.58B |
| Coloplast A/S | 27.03B |
| Zealand Pharma A/S | 76.87M |
| Demant A/S | 22.84B |
| H. Lundbeck A/S | 21.44B |
| H. Lundbeck A/S | 21.44B |
| ALK-Abelló A/S | 5.38B |
| Ambu A/S | 5.39B |
Genmab News
- 8 days ago - Genmab A/S: Circling Back On This Complicated Story - Seeking Alpha
- 10 days ago - Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 12 days ago - Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 13 days ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis - Business Wire
- 13 days ago - Genmab Is Too Attractive To Ignore - Seeking Alpha
- 14 days ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Business Wire
- 18 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 19 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire